See more : Maruzen Showa Unyu Co., Ltd. (9068.T) Income Statement Analysis – Financial Results
Complete financial analysis of Myomo, Inc. (MYO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Myomo, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- UPL Limited (UPL.NS) Income Statement Analysis – Financial Results
- Formuepleje Globale Aktier – Akkumulerende (FPIGAA.CO) Income Statement Analysis – Financial Results
- Fine besteel. Co., Ltd. (133820.KS) Income Statement Analysis – Financial Results
- Hindware Home Innovation Limited (HINDWAREAP.BO) Income Statement Analysis – Financial Results
- World Copper Ltd. (WCUFF) Income Statement Analysis – Financial Results
Myomo, Inc. (MYO)
About Myomo, Inc.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.24M | 15.56M | 13.86M | 7.58M | 3.84M | 2.44M | 1.56M | 1.10M | 689.67K | 913.25K |
| Cost of Revenue | 6.06M | 5.30M | 3.54M | 2.60M | 917.62K | 728.28K | 505.28K | 282.16K | 244.41K | 211.58K |
| Gross Profit | 13.18M | 10.25M | 10.31M | 4.98M | 2.92M | 1.72M | 1.05M | 821.11K | 445.26K | 701.67K |
| Gross Profit Ratio | 68.51% | 65.91% | 74.42% | 65.71% | 76.09% | 70.20% | 67.59% | 74.42% | 64.56% | 76.83% |
| Research & Development | 2.64M | 2.48M | 2.56M | 1.67M | 2.16M | 1.84M | 1.75M | 1.12M | 869.13K | 675.21K |
| General & Administrative | 16.02M | 14.37M | 14.44M | 12.98M | 11.25M | 10.41M | 5.85M | 2.93M | 3.10M | 2.85M |
| Selling & Marketing | 3.22M | 4.07M | 3.59M | 841.30K | 301.70K | 136.30K | 31.00K | 41.60K | 119.70K | 14.30K |
| SG&A | 18.78M | 18.44M | 18.02M | 13.82M | 11.55M | 10.41M | 5.85M | 2.98M | 3.22M | 2.86M |
| Other Expenses | 0.00 | -1.10K | -16.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.41M | 20.93M | 20.58M | 15.49M | 13.72M | 12.24M | 7.60M | 4.10M | 3.98M | 3.44M |
| Cost & Expenses | 27.47M | 26.23M | 24.12M | 18.09M | 14.63M | 12.97M | 8.11M | 4.38M | 4.22M | 3.65M |
| Interest Income | 410.27K | 88.73K | 1.61K | 474.71K | 112.49K | 0.00 | 0.00 | 0.00 | 196.06K | 178.86K |
| Interest Expense | 0.00 | 88.73K | 15.34K | 474.71K | 113.63K | 358.92K | 358.92K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 517.68K | 542.63K | 335.96K | 108.67K | 95.12K | 69.68K | 11.42K | 7.73K | 5.31K | 6.16K |
| EBITDA | -7.71M | -10.13M | -9.93M | -11.24M | -10.70M | -10.46M | -6.54M | -3.27M | -3.53M | -2.74M |
| EBITDA Ratio | -40.09% | -65.12% | -71.68% | -137.06% | -283.88% | -429.40% | -86.36% | -296.14% | -511.58% | -299.50% |
| Operating Income | -8.23M | -10.67M | -10.27M | -10.50M | -10.80M | -10.53M | -6.55M | -3.28M | -3.53M | -2.74M |
| Operating Income Ratio | -42.78% | -68.61% | -74.10% | -138.50% | -281.29% | -430.77% | -420.06% | -296.84% | -512.35% | -300.17% |
| Total Other Income/Expenses | 239.99K | 21.12K | -15.34K | -1.06M | 81.99K | 211.68K | -5.55M | -342.02K | -196.06K | -178.86K |
| Income Before Tax | -7.99M | -10.65M | -10.28M | -11.56M | -10.71M | -10.32M | -12.10M | -3.62M | -3.73M | -2.92M |
| Income Before Tax Ratio | -41.53% | -68.47% | -74.21% | -152.49% | -279.15% | -422.11% | -776.04% | -327.84% | -540.77% | -319.76% |
| Income Tax Expense | 156.00K | 69.94K | 88.93K | 474.71K | -81.99K | -247.95K | 5.57M | 342.02K | 752.61K | 607.62K |
| Net Income | -8.15M | -10.72M | -10.37M | -12.04M | -10.63M | -10.32M | -12.10M | -3.62M | -4.48M | -3.53M |
| Net Income Ratio | -42.34% | -68.92% | -74.86% | -158.75% | -277.01% | -422.11% | -776.04% | -327.84% | -649.90% | -386.29% |
| EPS | -0.28 | -1.52 | -1.78 | -3.62 | -19.20 | -25.18 | -84.05 | -0.56 | -134.56 | -106.03 |
| EPS Diluted | -0.28 | -1.52 | -1.78 | -3.62 | -19.20 | -25.15 | -84.05 | -0.56 | -134.56 | -106.03 |
| Weighted Avg Shares Out | 29.50M | 7.05M | 5.83M | 3.33M | 553.79K | 409.75K | 143.93K | 6.41M | 33.31K | 33.27K |
| Weighted Avg Shares Out (Dil) | 29.50M | 7.05M | 5.83M | 3.33M | 553.79K | 410.15K | 143.93K | 6.41M | 33.31K | 33.27K |
Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 14.89% and 4.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Myomo Reports Third Quarter 2022 Financial Results Featuring Strong Authorizations and Orders and Record Backlog
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September...
Myomo Reports Third Quarter 2022 Financial Results Featuring Strong Authorizations and Orders and Record Backlog
BOSTON--( BUSINESS WIRE )--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months...
Myomo To Present at the MicroCap Rodeo Presents The Windy City Roundup 2022
BOSTON, MA / ACCESSWIRE / October 5, 2022 / Myomo, Inc. (NYSE American:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis,...
Myomo to Present at the H.C. Wainwright 24th Annual Global Investment Conference
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will present at the H.C. Wainwright 24th Annual...
Myomo Receives Order from the Louis Stokes Cleveland VA Medical Center to Support MyoPro Clinical Trial
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced receipt of a $120,000 order for MyoPro® units from Cleveland's...
Myomo, Inc.'s (MYO) CEO Paul Gudonis on Q2 2022 Results - Earnings Call Transcript
Myomo, Inc. (NYSE:MYO ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Kim Golodetz - Investor Relations, LHA Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Ben Haynor...
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 6.67% and 4.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Myomo Reports Second Quarter 2022 Financial Results and Record Number of Patient Pipeline Additions
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June...
Myomo to Report Second Quarter Financial Results on August 3, 2022
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and...
Source: https://incomestatements.info
Category: Stock Reports